Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H32N4O2 |
| Molecular Weight | 420.5472 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC2(CN1CCN(C)CC1)C(=O)N(N(C2=O)C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=XGNKHIPCARGLGS-UHFFFAOYSA-N
InChI=1S/C25H32N4O2/c1-3-4-15-25(20-27-18-16-26(2)17-19-27)23(30)28(21-11-7-5-8-12-21)29(24(25)31)22-13-9-6-10-14-22/h5-14H,3-4,15-20H2,1-2H3
| Molecular Formula | C25H32N4O2 |
| Molecular Weight | 420.5472 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pipebuzone (LD 4644) is an anti-inflammatory, antipyretic and analgesic agent. Pipebuzone was used for the treatment of various rheumatic diseases. It was particularly well tolerated, clinically and pathologically, and had a reliable anti inflammatory action. This action was especially dramatic in the acute inflammatory rheumatisms and particularly in the microcrystalline arthropathies, gout and chondrocalcinosis. It was in the treatment of the latter that the drug was most consistently successful and quick acting. With chronic rheumatism its action was again noteworthy in the case of rheumatic pelvic spondylitis. Pipebuzone was also used in odonto-stomatology and maxillo-facial surgery, for the protection of the pulp in a conjoined prosthesis.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:02:40 GMT 2025
by
admin
on
Mon Mar 31 18:02:40 GMT 2025
|
| Record UNII |
2B2ZV6F5HG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3045
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
m1227
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
2B2ZV6F5HG
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
27315-91-9
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
3473
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
C008913
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
C66392
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105263
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
SUB09862MIG
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
100000081962
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
71917
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
DTXSID80181760
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY | |||
|
248-398-7
Created by
admin on Mon Mar 31 18:02:40 GMT 2025 , Edited by admin on Mon Mar 31 18:02:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |